Bavarian Nordic A/S
OTC: BVNRY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul John Chaplin
- Employees
- 1,645
- Headquarters
- Hellerup, Denmark
- IPO year
- 2013
- Market cap
- $2.1B
- Website
- https://www.bavarian-nordic.com
Loading BVNRY…
Loading profile data…Frequently asked questions about BVNRY
What does Bavarian Nordic A/S (BVNRY) do?
Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert...
Where does BVNRY trade?
Bavarian Nordic A/S (BVNRY) trades on the Other OTC.
What sector is BVNRY in?
Bavarian Nordic A/S (BVNRY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bavarian Nordic A/S?
Paul John Chaplin is the chief executive officer of Bavarian Nordic A/S (BVNRY).
Where is Bavarian Nordic A/S headquartered?
Bavarian Nordic A/S is headquartered in Denmark.
Does BVNRY pay a dividend?
Bavarian Nordic A/S (BVNRY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BVNRY go public?
Bavarian Nordic A/S (BVNRY) completed its initial public offering in 2013.
Is BVNRY an ADR?
Yes — BVNRY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Bavarian Nordic A/S reporting and dividends follow the underlying issuer.